A Phase 3 interventional study of Omecamtiv Mecarbil and Placebo in Heart Failure With Reduced Ejection Fraction, sponsored by Cytokinetics. Completed at 81 sites in 9 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-03-07.
Sponsored by Cytokinetics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing omecamtiv mecarbil in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. omecamtiv mecarbil · Heart Failure.
Among the 14 studies testing omecamtiv mecarbil in Heart Failure, this one is the 4th largest by enrollment, is the only one that started in 2019, is one of 4 in phase 3, and was the 12th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →1 of the 14 studies testing omecamtiv mecarbil in Heart Failure is open now, in 10 countries. Recruiting first, the newest first:
Cytokinetics · Sites in United States, Canada, China and 7 more countries
Ages 18–85
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2019.
This study's enrollment of 276 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 48 across the 14 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 14 have an industry lead sponsor. The 1 most frequent:
Cytokinetics is the lead sponsor of 41 studies on the registry; 3 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.
15 studies in Heart Failure by Cytokinetics: 2 open now, 2 under way, 1 of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 15 studies in Heart Failure by Cytokinetics, this one is the 4th largest by enrollment, is the only one that started in 2019, is one of 4 in phase 3, and was the 12th registered.
Cytokinetics’s Heart Failure studies by the year they started, since 2005.
1 of the studies testing omecamtiv mecarbil in Heart Failure that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing omecamtiv mecarbil in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Cytokinetics’s 15 in Heart Failure:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv mecarbil or placebo
Oversight Authorities:
United States: Food and Drug Administration Canada: Health Canada France: National Agency for the Safety of Medicine and Health Products Germany: Federal Institute for Drugs and Medical Devices Hungary: National Institute of Pharmacy and Nutrition Italy: Italian Medicines Agency Netherlands: Medicines Evaluation Board Poland: Chief Pharmaceutical Inspectorate Sweden: Medical Products Agency
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Omecamtiv mecarbil was administered as an oral modified-release tablet twice daily for up to 20 weeks. Participants randomized to this arm started at an omecamtiv mecarbil dose of 25 mg twice daily. The dose could be increased based on plasma concentrations at Weeks 2 and 6.
Drug: Omecamtiv Mecarbil
Participants randomized this arm received placebo tablets (matching the appearance of the omecamtiv mecarbil tablets) twice daily for up to 20 weeks.
Drug: Placebo
Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing
Also known as: CK-1827452, AMG-423
Oral placebo twice daily for up to 20 weeks
Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20
The effect of treatment on exercise capacity, as assessed by peak oxygen uptake, was assessed during cardiopulmonary exercise testing (CPET) with gas-exchange analysis. Cycle ergometry was the preferred modality for exercise testing; treadmill exercise testing was an acceptable alternative. Participants were to use the same testing modality for all exercise tests during the study. Whenever possible, CPET was administered by the same study personnel using the same equipment throughout the study.
Time frame: Baseline and Week 20
Change in Total Workload During Cardiopulmonary Exercise Testing From Baseline to Week 20
Total workload was measured during CPET (cycle ergometry \[preferred\] or treadmill exercise testing) and represents the maximum load to which a participant was subjected during CPET in order to produce work.
Time frame: Baseline and Week 20
Change in Ventilatory Efficiency During Cardiopulmonary Exercise Testing From Baseline to Week 20
Ventilatory efficiency (ventilation \[VE\]/volume of exhaled carbon dioxide \[VCO2\]) was measured through CPET with gas exchange analysis.
Time frame: Baseline and Week 20
Change in the Average Daily Activity Units Measured Over a 2-week Period From Baseline (Week -2 to Day 1) to Weeks 18-20
The effect of treatment on daily activity, as assessed by average daily activity units, was evaluated by actigraphy. Actigraphy was collected during 4 sessions throughout the study for 2 week intervals.
Time frame: Baseline (Week -2 to Day 1) to Weeks 18-20
Participants with heart failure with reduced ejection fraction (HFrEF) were enrolled at 63 sites in Canada, France, Germany, Hungary, Italy, Netherlands, Poland, Sweden, and the United States. The first participant enrolled on 09 April 2019, and the last participant completed follow-up on 06 January 2022.
| Milestone | Omecamtiv Mecarbil | Placebo |
|---|---|---|
| Started | 185 | 91 |
| Completed | 164 | 85 |
| Not completed | 21 | 6 |
| Withdrew: Adverse event | 12 | 4 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Consistently forgot to bring study drug kits to site visits (for compliance check) | 1 | 0 |
| Withdrew: No longer able to take medicines | 1 | 0 |
| Withdrew: Stopped taking study drug | 1 | 0 |
The effect of treatment on exercise capacity, as assessed by peak oxygen uptake, was assessed during cardiopulmonary exercise testing (CPET) with gas-exchange analysis. Cycle ergometry was the preferred modality for exercise testing; treadmill exercise testing was an acceptable alternative. Participants were to use the same testing modality for all exercise tests during the study. Whenever possible, CPET was administered by the same study personnel using the same equipment throughout the study.
| mL/min/kg | Omecamtiv Mecarbil | Placebo |
|---|---|---|
| Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20 | -0.239 ± 0.1718 | 0.207 ± 0.2412 |
Total workload was measured during CPET (cycle ergometry \[preferred\] or treadmill exercise testing) and represents the maximum load to which a participant was subjected during CPET in order to produce work.
| Watt | Omecamtiv Mecarbil | Placebo |
|---|---|---|
| Change in Total Workload During Cardiopulmonary Exercise Testing From Baseline to Week 20 | -3.798 ± 1.3352 | 1.590 ± 1.9477 |
Ventilatory efficiency (ventilation \[VE\]/volume of exhaled carbon dioxide \[VCO2\]) was measured through CPET with gas exchange analysis.
| slope | Omecamtiv Mecarbil | Placebo |
|---|---|---|
| Change in Ventilatory Efficiency During Cardiopulmonary Exercise Testing From Baseline to Week 20 | 0.277 ± 0.3616 | -0.138 ± 0.5065 |
The effect of treatment on daily activity, as assessed by average daily activity units, was evaluated by actigraphy. Actigraphy was collected during 4 sessions throughout the study for 2 week intervals.
| 10^5 activity units | Omecamtiv Mecarbil | Placebo |
|---|---|---|
| Change in the Average Daily Activity Units Measured Over a 2-week Period From Baseline (Week -2 to Day 1) to Weeks 18-20 | -0.2 ± 0.30 | -0.5 ± 0.38 |
Collected over Adverse events were collected from randomization through the end of study/safety follow-up visit (scheduled to occur 4 weeks after the last dose of study drug) or 30 days after the last dose of study drug, whichever was later.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Omecamtiv Mecarbil | 3/185 (1.6%) | 30/185 (16.2%) | 126/185 (68.1%) |
| Placebo | 1/91 (1.1%) | 13/91 (14.3%) | 58/91 (63.7%) |
| Event | Omecamtiv Mecarbil | Placebo |
|---|---|---|
| Cardiac failureCardiac disorders | 7/185 | 1/91 |
| Cardiac failure acuteCardiac disorders | 2/185 | 3/91 |
| Ventricular tachycardiaCardiac disorders | 5/185 | 2/91 |
| Acute myocardial infarctionCardiac disorders | 0/185 | 2/91 |
| Atrial fibrillationCardiac disorders | 2/185 | 1/91 |
| Supraventricular tachycardiaCardiac disorders | 0/185 | 1/91 |
| Abscess limbInfections and infestations | 0/185 | 1/91 |
| Urinary tract infectionInfections and infestations | 0/185 | 1/91 |
| Ischaemic strokeNervous system disorders | 0/185 | 1/91 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/185 | 1/91 |
| Event | Omecamtiv Mecarbil | Placebo |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/185 | 8/91 |
| DizzinessNervous system disorders | 9/185 | 5/91 |
| FatigueGeneral disorders | 9/185 | 4/91 |
| Back painMusculoskeletal and connective tissue disorders | 5/185 | 4/91 |
| DiarrhoeaGastrointestinal disorders | 7/185 | 4/91 |
| RashSkin and subcutaneous tissue disorders | 0/185 | 4/91 |
| FallInjury, poisoning and procedural complications | 7/185 | 1/91 |
| Angina pectorisCardiac disorders | 4/185 | 3/91 |
| Atrial fibrillationCardiac disorders | 4/185 | 3/91 |
| Non-cardiac chest painGeneral disorders | 4/185 | 3/91 |
| Age, Continuous(years) | Omecamtiv Mecarbil | Placebo | Total |
|---|---|---|---|
| Mean | 63.3 ± 9.64 | 64.4 ± 11.41 | 63.6 ± 10.25 |
| Sex: Female, Male(Participants) | Omecamtiv Mecarbil | Placebo | Total |
|---|---|---|---|
| Female | 27 | 15 | 42 |
| Male | 158 | 76 | 234 |
| Race (NIH/OMB)(Participants) | Omecamtiv Mecarbil | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 16 | 6 | 22 |
| White | 163 | 82 | 245 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Time since HFrEF diagnosis(years) | Omecamtiv Mecarbil | Placebo | Total |
|---|---|---|---|
| Mean | 7.6 ± 6.14 | 7.8 ± 6.88 | 7.7 ± 6.38 |
| Primary cause of heart failure: ischemic heart disease(Participants) | Omecamtiv Mecarbil | Placebo | Total |
|---|---|---|---|
| Count of participants | 117 | 48 | 165 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Apr 2019 to primary completion in Nov 2021, 30 months.
Results were first posted in Mar 2023, 1 year 3 months after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 30 months is below that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omecamtiv mecarbil